Preliminary evaluation of 177Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy

  • Lei Jiang
  • Zheng Miao
  • Richard H. Kimura
  • Hongguang Liu
  • Jennifer R. Cochran
  • Cathy S. Culter
  • Ande Bao
  • Peiyong Li
  • Zhen Cheng
Original Article

DOI: 10.1007/s00259-010-1684-x

Cite this article as:
Jiang, L., Miao, Z., Kimura, R.H. et al. Eur J Nucl Med Mol Imaging (2011) 38: 613. doi:10.1007/s00259-010-1684-x

Abstract

Purpose

Cystine knot peptides (knottins) 2.5D and 2.5F were recently engineered to bind integrin receptors with high affinity and specificity. These receptors are overexpressed on the surface of a variety of malignant human tumor cells and tumor neovasculature. In this study, 2.5D and 2.5F were labeled with a therapeutic radionuclide, 177Lu, and the resulting radiopeptides were then evaluated as potential radiotherapeutic agents in a murine model of human glioma xenografts.

Methods

Knottins 2.5D and 2.5F were synthesized using solid phase peptide synthesis, folded in vitro, and site-specifically coupled with 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid (DOTA) at their N terminus for 177Lu radiolabeling. The stability of the radiopeptides 177Lu-DOTA-2.5D and 177Lu-DOTA-2.5F was tested in both phosphate-buffered saline (PBS) and mouse serum. Cell uptake assays of the radiolabeled peptides were performed in U87MG integrin-expressing human glioma cells. The biodistribution studies of both 177Lu-DOTA-2.5D and 177Lu-DOTA-2.5F were examined in U87MG tumor-bearing athymic nu/nu mice. Radiation absorbed doses for the major tissues of a human adult male were calculated based on the mouse biodistribution results.

Results

DOTA-2.5D and DOTA-2.5F were labeled with 177Lu at over 55% efficiency. High radiochemical purity for both radiocomplexes (> 95%) could be achieved after high performance liquid chromatography (HPLC) purification. Both radiopeptides were stable in PBS and mouse serum. Compared to 177Lu-DOTA-2.5D (0.39 and 0.26 %ID/g at 2 and 24 h, respectively), 177Lu-DOTA-2.5F showed much higher tumor uptake (2.16 and 0.78 %ID/g at 2 and 24 h, respectively). It also displayed higher tumor to blood ratios than that of 177Lu-DOTA-2.5D (31.8 vs 18.7 at 24 h and 52.6 vs 20.6 at 72 h). Calculation of radiodosimetry for 177Lu-DOTA-2.5D and 177Lu-DOTA-2.5F suggested that tumor and kidney were tissues with the highest radiation absorbed doses. Moreover, 177Lu-DOTA-2.5F had a higher tumor to kidney radiation absorbed dose ratio than that of 177Lu-DOTA-2.5D.

Conclusion

Cystine knot peptides can be successfully radiolabeled with 177Lu for potential therapeutic applications. Knottin 2.5F labeled with 177Lu exhibits favorable distribution in murine U87MG xenograft model; thus, it is a promising agent for radionuclide therapy of integrin-positive tumors.

Keywords

177Lu Cystine knot peptide Integrin Radionuclide therapy 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Lei Jiang
    • 1
    • 2
  • Zheng Miao
    • 2
  • Richard H. Kimura
    • 3
  • Hongguang Liu
    • 2
  • Jennifer R. Cochran
    • 3
  • Cathy S. Culter
    • 4
  • Ande Bao
    • 5
  • Peiyong Li
    • 1
  • Zhen Cheng
    • 2
  1. 1.Department of Nuclear Medicine, Shanghai Ruijin HospitalShanghai Jiaotong UniversityShanghaiPeople’s Republic of China
  2. 2.Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford Cancer Center, Bio-X ProgramStanford UniversityStanfordUSA
  3. 3.Department of Bioengineering, Stanford Cancer Center, Bio-X ProgramStanford UniversityStanfordUSA
  4. 4.Research Reactor CenterUniversity of MissouriColumbiaUSA
  5. 5.Departments of Radiology and Otolaryngology – Head and Neck SurgeryUniversity of Texas Health Science Center at San AntonioSan AntonioUSA

Personalised recommendations